Compare GDS & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDS | RGEN |
|---|---|---|
| Founded | 2001 | 1981 |
| Country | China | United States |
| Employees | 2434 | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.6B |
| IPO Year | N/A | 1995 |
| Metric | GDS | RGEN |
|---|---|---|
| Price | $29.83 | $142.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $45.27 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $141,236,000.00 |
| Revenue This Year | $12.93 | $14.30 |
| Revenue Next Year | $13.27 | $14.52 |
| P/E Ratio | ★ $52.69 | $927.07 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $26.97 | $100.99 |
| 52 Week High | $48.61 | $175.77 |
| Indicator | GDS | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 61.53 |
| Support Level | $26.97 | $123.05 |
| Resistance Level | $37.45 | $141.46 |
| Average True Range (ATR) | 1.62 | 6.31 |
| MACD | 0.08 | 0.44 |
| Stochastic Oscillator | 22.30 | 68.45 |
GDS Holdings started as an IT service provider in 2001, then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates, and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China, and it has also started expanding into Southeast Asia via the now 23% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.